QT correction methods in children and adolescents

Journal of Cardiovascular Electrophysiology

Volumn 16, Issue 1, 2005, Pages 76-80

  Wernicke, Joachim F ^a   Faries, Douglas ^a   Breitung, Rebecca ^a   Girod, Donald ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Cardiac repolarization; Children; QT interval; QTc

Indexed keywords

ACCURACY; ADOLESCENT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; DATA BASE; ELECTROCARDIOGRAM; FEMALE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL; SEX DIFFERENCE; SYSTEMATIC REVIEW;

EID: 12844264651     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2005.03520.x     Document Type: Article

References (15)

1. Draft Consensus Guidelines: Available at http://www.fda.gov/ OHRMS/DOCKETS/98fr/061402f.pdf.
2. Walsh G, Annunziato L, Frossard N, Knol K, Levander S, Nicolas J, Tagliatatela M, Tharp M, Tillement J, Timmerman H: New insights into the second generation antihistamines. Drugs 2001;61:207-236.
3. Michalets EL, Williams CR: Drug interactions with cisapride: Clinical implications. Clin Pharmacokinet 2000;39:49-75.
4. Ponti F, Puluzzi E, Cavalli A, Recanatini M, Montanaro N: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Safety 2002;25:263-286.
5. Moss AJ: Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993;72:23B-25B.
6. Func-Brantano C, Jaillon P: Rate-corrected QT interval: Techniques and limitations. Am J Cardiol 1993;72:17B-22B.
7. Moss AJ: Long QT syndrome. JAMA 2003;289:2041-2044.
8. Wernicke J, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Safety 2003;26:12.
9. Wernicke J, Kratochvil C: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(Suppl 12):50-55.
10. Michelson D, Allen A, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee F, Sangal R, Saylor K, West S, Kelsey D, Wernicke J, Trapp N, Harder D: Once-daily atomoxeline treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901.
11. Kratochvil C, Heiligenstein J, Dittmann R, Spencer T, Biederman J, Wernicke J, Newcorn J, Casat C, Milton D, Michelson D: Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:784.
12. Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N: Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Safety 2002;25:263-286.
13. Malik M, Camm A: Evaluation of drug-induced QT interval prolongation. Drug Safety 2001;24:323-351.
14. Dmitrienko A, Smith BP: Analysis of the QT interval in clinical trials. Drug Int J 2002;36:269-279.
15. Committee for Proprietary Medicinal Products: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, London: The European Agency for he Evaluation of Medicinal Products, Human Medicines Evaluation Unit. December 17, 1997. Report no. CPMP/986/96.